Table 1 Comparison of the percentage inhibition of renal glucose reabsorption of different SGLT-inhibitors
From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
| Drug dosage | Filtered glucose (g/24 h) (eGFRx mean glucose mg/mL) | UGE (g/24 h) | Absorbed glucose (g/24 h) | Inhibition of glucose reabsorption (%) | References |
|---|---|---|---|---|---|
| Sotagliflozin 150 mg | 256 | 36 | 220 | 14.1 | Zambrowicz et al. [15] |
| Sotagliflozin 300 mg | 287.5 | 47 | 240 | 16.5 | |
| Sotagliflozin 200 mg, 200 mg bid, 400 mg | – | ~60 | – | – | Rosentock et al. [36] |
| Empagliflozin 2.5 mg | – | – | – | 39 | Heise et al. [37] |
| Empagliflozin 10 mg | – | – | – | 46 | |
| Empagliflozin 25 mg | – | – | – | 58 | |
| Empagliflozin 100 mg | – | – | – | 64 | |
| Dapagliflozin 2.5 mg | 191.16 | 52 | 139.16 | 27.2 | List et al. [38] |
| Dapagliflozin 5 mg | 207.6 | 64 | 143.6 | 55.7 | |
| Dapagliflozin 10 mg | 206.1 | 68 | 138.1 | 54.5 | |
| Dapagliflozin 20 mg | 196.9 | 85 | 111.9 | 51.7 | |
| Dapagliflozin 50 mg | 191.3 | 82 | 109.3 | 53.1 |